{"id":"NCT01471574","sponsor":"Bristol-Myers Squibb","briefTitle":"Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus","officialTitle":"A Phase 3, Open Label Study of Safety and Efficacy With BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected With Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2014-06","completion":"2014-09","firstPosted":"2011-11-15","resultsPosted":"2015-12-17","lastUpdate":"2016-01-29"},"enrollment":549,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Genotype 1"],"interventions":[{"type":"DRUG","name":"Daclatasvir","otherNames":["BMS-790052"]},{"type":"DRUG","name":"Ribavirin","otherNames":["Copegus®"]},{"type":"DRUG","name":"PEG-Interferon alfa 2a","otherNames":["Pegasys®","Pegylated interferon"]}],"arms":[{"label":"Daclatsvir + Ribavirin + PEG-Interferon alfa-2a","type":"EXPERIMENTAL"}],"summary":"The purpose of this open label study is to evaluate the safety and efficacy of daclatasvir plus pegylated interferon-alfa 2a and ribavirin in untreated hepatitis C virus in patients coinfected with HIV","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)","timeFrame":"Follow-up Week 12","effectByArm":[{"arm":"Highly Active Anti-Retroviral Therapy (HAART):Daclatasvir,30mg","deltaMin":75,"sd":null},{"arm":"HAART Therapy: Daclatasvir, 60 mg","deltaMin":71.8,"sd":null},{"arm":"HAART: Daclatasvir, 30 mg + 60 mg","deltaMin":71.7,"sd":null},{"arm":"HAART Therapy: Daclatasvir 30 or 60 or 90 mg","deltaMin":73.3,"sd":null},{"arm":"Non-HAART Therapy: Daclatasvir, 60 mg","deltaMin":87.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":86,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","France","Germany","Italy","Puerto Rico","Russia","Spain","United Kingdom"]},"refs":{"pmids":["28210927"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":132},"commonTop":["Fatigue","Neutropenia","Anaemia","Asthenia","Headache"]}}